1.A Case of Possible Doxycycline-Resistant Scrub Typhus.
Dong Jib NA ; Sang Hoon HAN ; Kyung Min MOON ; Dong Jin KIM ; Yang Deok LEE ; Yong Seon CHO ; Min Soo HAN ; Hee Jung YOON
Tuberculosis and Respiratory Diseases 2007;62(6):545-548
No abstract available.
Clarithromycin
;
Doxycycline
;
Scrub Typhus*
2.Add-on Clarithromycin and Tacrolimus Treatment for Rheumatoid Arthritis.
Journal of Rheumatic Diseases 2017;24(2):123-124
No abstract available.
Arthritis, Rheumatoid*
;
Clarithromycin*
;
Tacrolimus*
4.Cutaneous Mycobacterium massiliense Infection of the Sole of the Feet.
Mi Young JUNG ; Jae Hyoung LEE ; Cho Rok KIM ; Hyun Je KIM ; Won Jung KOH ; Chang Suk KI ; Joo Heung LEE ; Jun Mo YANG ; Dong Youn LEE
Annals of Dermatology 2014;26(1):92-95
Mycobacterium massiliense which is recognized as a separate species from M. abscessus is little known regarding its clinical patterns and the response to treatment. We present a case of a localized cutaneous infection due to M. massiliense of the sole associated with acupuncture. M. massiliense was identified via polymerase chain reaction-hybridization analysis. We treated the patient with single-drug therapy consisting of clarithromycin for 4 months and the patient showed a significant response to this treatment.
Acupuncture
;
Clarithromycin
;
Foot*
;
Humans
;
Mycobacterium*
5.Successful Treatment of Polymyalgia Rheumatica with Prednisolone in Combination with Clarithromycin and Tacrolimus
Journal of Rheumatic Diseases 2018;25(1):73-75
No abstract available.
Clarithromycin
;
Polymyalgia Rheumatica
;
Prednisolone
;
Tacrolimus
6.Comparison of Modified Broth Microdilution Method, E test, and Disk Diffusion Method for Antimicrobial Susceptibility Testing of Helicobacter pylori.
Eun Suk KIM ; Jung Oak KANG ; Dongsoo HAN ; Pil Whan PARK ; Ile Kyu PARK ; Tae Yeal CHOI
Korean Journal of Clinical Pathology 1998;18(4):559-564
BACKGROUND: The emergence of metronidazole (MTZ) resistance among Helicobacter pylori (H. pylori) isolates has compromised the efficacy of the triple therapy. Therefore, special attention should be given toward reliable methods for determining the in vitro susceptibility. But susceptibility testing of H. pylori is not yet either standardized or routinely performed. The purpose of this study was to establish more reliable, but simple to perform and cost-effective antimicrobial susceptibility testing method. METHODS: With 135 clinical isolates of H. pylori, antimicrobial susceptibility tests for MTZ and clarithromycin (CLR) were performed by antibiotic gradient method (E test, AB BIODISK, Sweden) and disk diffusion method (disk method), and the results were compared with the reference modified broth microdilution method (broth method). RESULTS: Resistant rates of Korean isolates of H. pylori for MTZ and CLR were 46.2% and 2.2%, respectively. There was 100% agreements between the E test, disk method and the broth method for CLR. For MTZ, however, agreements between the results obtained by the three methods were variable. Between the E test and broth method, the agreements were 85.1% in terms of susceptibility categories, 80.5% between the disk and broth method, and 93.1% between the E test and disk method. CONCLUSIONS: Routine susceptibility testing of H. pylori to MTZ seems to be required in Korea. The broth method is recommended for MTZ until more accurate, simple and practical alternative method become available. For the CLR, the disk method is recommended, because it is reliable, simple, and economical.
Clarithromycin
;
Diffusion*
;
Helicobacter pylori*
;
Helicobacter*
;
Korea
;
Metronidazole
7.Identification of Cutaneous Mycobacterium massiliense Infections Associated with Repeated Surgical Procedures.
Ah Young CHO ; Yeon Sook KIM ; Yoon Hoh KOOK ; Shin Ok KIM ; Seung Ju BACK ; Young Joon SEO ; Jeung Hoon LEE ; Young LEE
Annals of Dermatology 2010;22(1):114-118
Mycobacterium massiliense, an emerging pathogen that is increasingly reported as a causative agent in infections occurring during medical procedures, is difficult to be identified using conventional methods. Here we report the case of a cutaneous M. massiliense infection that was associated with repeated surgical procedures and that was identified via a comparative sequence analysis of rpoB and hsp65. The patient showed a substantial response to treatment with a combination of antimicrobial therapies consisting of clarithromycin, amikacin, and cefoxitin for 6 months.
Amikacin
;
Cefoxitin
;
Clarithromycin
;
Humans
;
Mycobacterium
;
Sequence Analysis
8.Successful treatment of angioimmunoblastic T-cell lymphoma with clarithromycin.
Blood Research 2016;51(2):139-142
No abstract available.
Clarithromycin*
;
Lymphoma, T-Cell*
;
T-Lymphocytes*
9.Successful treatment of angioimmunoblastic T-cell lymphoma with clarithromycin.
Blood Research 2016;51(2):139-142
No abstract available.
Clarithromycin*
;
Lymphoma, T-Cell*
;
T-Lymphocytes*
10.Eradication of a Helicobacter Pylori Using Omeprazole, Clarithromycin and Metronidazole in Peptic Ulcer Diseases.
Byoung Gue NA ; Jae Hong CHOI ; Sang Woo OH ; Jee Hyun LEE ; Sang Moo JUNG ; Seon Mee PARK ; Sae Jin YOUN
Korean Journal of Gastrointestinal Endoscopy 1998;18(3):312-318
BACKGROUND/AIMS: The aim of this study was to ascertain the effects of two week treatment of omeprazole (O) and clarithromycin (C) with and without metronidazole (M), and one week treatment of omeprazole, clarithromycin and metronidazole, for the eradieation of Helicobacter pylori (H. pylori) in patients with peptic ulcer disease in double-blind, randomly controlled groups. METHODS: The H. pylori infection determined in patients whose results were positive in a rapid urease test or in those who exhibited histology in antrum and body, The OC14 group received O 40 mg qd and C 500 mg t.i.d. for 2 weeks; the OCM14 group received O, C, and M 250 mg t.i.d for 2 weeks, and the OCM7 group received O, C, M for 1 week, respectively. H. pylori eradication was assessed 4 weeks after the end of treatment. The H. pylori eradication was determined as all negative for the rapid urease test and histology on both the antrum and body.
Clarithromycin*
;
Helicobacter pylori*
;
Helicobacter*
;
Humans
;
Metronidazole*
;
Omeprazole*
;
Peptic Ulcer*
;
Urease